Randall Stanicky
Stock Analyst at RBC Capital
(2.52)
# 2,328
Out of 4,954 analysts
31
Total ratings
66.67%
Success rate
8.67%
Average return
Main Sectors:
Stocks Rated by Randall Stanicky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $129 → $135 | $206.19 | -34.53% | 10 | Feb 4, 2021 | |
| PRGO Perrigo Company | Downgrades: Sector Perform | $59 → $49 | $23.60 | +107.63% | 8 | Jan 6, 2021 | |
| PFE Pfizer | Downgrades: Sector Perform | $43 → $42 | $25.32 | +65.88% | 3 | Dec 16, 2020 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $170 → $180 | $119.20 | +51.01% | 2 | Nov 3, 2020 | |
| MRK Merck & Co. | Maintains: Sector Perform | $92 → $89 | $84.93 | +4.79% | 1 | Apr 1, 2020 | |
| AMRX Amneal Pharmaceuticals | Maintains: Sector Perform | $3 → $4 | $9.33 | -57.13% | 3 | Jan 2, 2020 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Underperform | n/a | $17.56 | - | 3 | Aug 4, 2017 | |
| PCRX Pacira BioSciences | Initiates: Outperform | $58 | $25.19 | +130.25% | 1 | Apr 13, 2017 |
AbbVie
Feb 4, 2021
Maintains: Outperform
Price Target: $129 → $135
Current: $206.19
Upside: -34.53%
Perrigo Company
Jan 6, 2021
Downgrades: Sector Perform
Price Target: $59 → $49
Current: $23.60
Upside: +107.63%
Pfizer
Dec 16, 2020
Downgrades: Sector Perform
Price Target: $43 → $42
Current: $25.32
Upside: +65.88%
Jazz Pharmaceuticals
Nov 3, 2020
Maintains: Outperform
Price Target: $170 → $180
Current: $119.20
Upside: +51.01%
Merck & Co.
Apr 1, 2020
Maintains: Sector Perform
Price Target: $92 → $89
Current: $84.93
Upside: +4.79%
Amneal Pharmaceuticals
Jan 2, 2020
Maintains: Sector Perform
Price Target: $3 → $4
Current: $9.33
Upside: -57.13%
Teva Pharmaceutical Industries
Aug 4, 2017
Downgrades: Underperform
Price Target: n/a
Current: $17.56
Upside: -
Pacira BioSciences
Apr 13, 2017
Initiates: Outperform
Price Target: $58
Current: $25.19
Upside: +130.25%